Insider · CIK 0001727388
Daphne Zohar
Files at SPTX (Seaport Therapeutics, Inc.). First filing -, latest -.
In brief
Daphne Zohar files SEC Form 4 as CEO and director at SPTX (Seaport Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Daphne Zohar has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | SPTX Seaport Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +271,813 | $0.00 | $0 | 271,813 | May 4, 2026 |
| Apr 30, 2026 | SPTX Seaport Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,486,786 | $0.00 | $0 | 1,486,786 | May 4, 2026 |
Questions about Daphne Zohar
Answered from the filings on this page, as of the latest one.
Is Daphne Zohar buying or selling?
Daphne Zohar has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Daphne Zohar's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Daphne Zohar has 0.
Where does Daphne Zohar file Form 4?
Daphne Zohar has filed Form 4 at SPTX (Seaport Therapeutics, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.